(thirdQuint)A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL.

 This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered weekly by IV infusion to adults diagnosed with LGL or CTCL.

 The study has four periods: - Screening Period - 4-week Treatment Period - 3-month Treatment Extension Period - 6-week Follow-up Period Subjects will be screened for eligibility within 30 days of study Day 1 (first dosing day of the 4-Week Treatment Period).

.

 A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL@highlight

This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered weekly by IV infusion to adults diagnosed with Large Granular Lymphocyte (LGL) Leukemia or refractory Cutaneous T-cell Lymphoma (CTCL).

